Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002) (KCC-SMT-002)
An Open-Label Phase 1 Study to Establish the Pharmacokinetics and Safety of Sumatriptan Succinate Administered Via the Sofusa™ DoseConnect™ System at Escalating Doses Compared to Oral Imitrex® Single 100 mg Dose in Healthy Subjects
Sponsor: Kimberly-Clark Corporation
A PHASE1 clinical study on Migraine Disorders, this trial is completed. The trial is conducted by Kimberly-Clark Corporation and has accumulated 10 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Jan 2021 — Sep 2022 [monthly]
Unknown Status PHASE1
-
May 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Feb 2020 — May 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Not Yet Recruiting → Active Not Recruiting
-
Dec 2017 — May 2018 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kimberly-Clark Corporation
- Sorrento Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .